Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 15/20 | 1.00 |
| ▸ | CA2 | P00918 | 15/20 | 1.00 |
| ▸ | CA4 | P22748 | 7/20 | 1.00 |
| ▸ | CA9 | Q16790 | 7/20 | 1.00 |
| ▸ | CA12 | O43570 | 6/20 | 1.00 |
| ▸ | CA6 | P23280 | 6/20 | 1.00 |
| ▸ | CA5A | P35218 | 6/20 | 1.00 |
| ▸ | CA7 | P43166 | 6/20 | 1.00 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 1.00 |
| ▸ | CA5B | Q9Y2D0 | 6/20 | 1.00 |
| ▸ | CA3 | P07451 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.50 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30659050 | 1.00 | CA1 (1.00) | CA1CA2CA4CA9CA12 | |
| SCHEMBL29376122 | 1.00 | CA1 (1.00) | CA1CA2CA4CA9CA12 | |
| Acetamide SCHEMBL25369769 | 0.89 | CA1 (0.79) | CA1CA2CA4CA9CA12 | |
| SCHEMBL1807804 | 0.88 | CA1 (0.79) | CA1CA2CA4CA9CA12 | |
| SCHEMBL11132234 | 0.88 | CA1 (0.79) | CA1CA2CA4CA9CA12 | |
| SCHEMBL9647910 | 0.88 | CA1 (0.78) | CA1CA2CA4CA9CA12 | |
| SCHEMBL27903562 | 0.88 | CA1 (0.78) | CA1CA2CA4CA9CA12 | |
| SCHEMBL26514797 | 0.88 | CA1 (0.78) | CA1CA2CA4CA9CA12 | |
| Hydrochloric Acid SCHEMBL11139867 | 0.86 | CA1 (0.76) | CA1CA2CA4CA9CA12 | |
| SCHEMBL1806519 | 0.86 | CA1 (0.76) | CA1CA2CA4CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1423 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118243799-A | Detection method of valsartan hydrochlorothiazide related substances | 珠海润都制药股份有限公司 | 2024-06-25 | — | — | CN | claimed |
| CN-114614058-B | Thin-layer composite proton exchange membrane and preparation method and application thereof | 中国石油化工股份有限公司 | 2024-05-07 | — | — | CN | claimed |
| CN-114369073-B | Method for preparing high-purity hydrochlorothiazide | 润都制药(荆门)有限公司 | 2024-03-26 | — | — | CN | claimed |
| CN-116769441-A | Preparation method of underwear back button and product | 广东启悦未来科技股份有限公司 | 2023-09-19 | — | — | CN | claimed |
| CN-114432903-B | Composite membrane with acid resistance and preparation method and application thereof | 中国石油化工股份有限公司 | 2023-03-14 | — | — | CN | claimed |
| EP-3670490-B1 | METHOD OF PURIFYING PINE CHEMICAL COMPOSITIONS FROM ALDEHYDES | KRATON POLYMERS LLC (US) | 2023-01-18 | — | — | EP | claimed |
| CN-114614058-A | Thin-layer composite proton exchange membrane and preparation method and application thereof | 中国石油化工股份有限公司 | 2022-06-10 | — | — | CN | claimed |
| CN-114432903-A | Composite membrane with acid resistance and preparation method and application thereof | 中国石油化工股份有限公司 | 2022-05-06 | — | — | CN | claimed |
| CN-114369073-A | Method for preparing high-purity hydrochlorothiazide | 润都制药(荆门)有限公司 | 2022-04-19 | — | — | CN | claimed |
| CN-113588828-A | Method for simultaneously detecting forty-eight stimulants in animal-derived food | 西安市食品药品检验所(西安市药品不良反应监测中心) | 2021-11-02 | — | — | CN | claimed |
| EP-1507813-A1 | FAT BINDING USING INTER-POLYMER COMPLEX OF GLUCOSAMINE AND POLYACRYLIC ACID | Ranbaxy Laboratories Limited (IN) | 2005-02-23 | — | — | EP | claimed |
| EP-1385501-A2 | PROBUCOL MONOESTERS AND THEIR USE TO INCREASE PLASMA HDL CHOLESTEROL LEVELS AND IMPROVE HDL FUNCTIONALITY | Atherogenics, Inc. (US) | 2004-02-04 | — | — | EP | claimed |
| WO-2003097714-A1 | FAT BINDING USING INTER-POLYMER COMPLEX OF GLUCOSAMINE AND POLYACRYLIC ACID | RANBAXY LABORATORIES LIMITED (IN) | 2003-11-27 | — | — | WO | claimed |
| US-20030162824-A1 | Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor | PHARMACIA CORPORATION | 2003-08-28 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| WO-2002087556-A9 | PROBUCOL MONOESTERS AND THEIR USE TO INCREASE PLASMA HDL CHOLESTEROL LEVELS AND IMPROVE HDL FUNCTIONALITY | ATHEROGENICS INC (US) | 2003-03-20 | — | — | WO | claimed |
| WO-2002087556-A2 | PROBUCOL MONOESTERS AND THEIR USE TO INCREASE PLASMA HDL CHOLESTEROL LEVELS AND IMPROVE HDL FUNCTIONALITY | ATHEROGENICS, INC. (US) | 2002-11-07 | — | — | WO | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162824-A1 | Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor | PTGS1, PTGIS, TNNT2 | CA1 1067/4885CA2 217/4885CA4 1070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.